Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Parkinson’s Neurons Form Atypical Networks

Parkinson’s disease brain cells form abnormal networks that might predispose the cells toward damage, according to new research done using cells in laboratory conditions. “These discoveries open the door to early diagnosis, which would allow us to carry out a premature intervention that would slow down neuronal death, and…

Voice-assisted Devices May Help Patients to Speak More Clearly

People with Parkinson’s disease who use voice-assisted technologies (VATs) — software programs that respond to voice commands, like Amazon’s Alexa or Apple’s Siri — may find that they help to improve their speech by prodding them to practice speaking more clearly, a study based on an online patient survey…

Stem Cell Therapy Shows Safety, Possible Efficacy in Early Trial

Treatment with ISC-hpNSC, an investigational stem cell therapy for Parkinson’s disease, was safe and well-tolerated over at least two years in an early clinical trial in 12 patients. Results from the small trial, which treated patients at low, medium and high doses, also indicate that the therapy eased Parkinson’s-related symptoms…

Differences in Mouse, Human Astrocytes May Impact Research

Brain cells called astrocytes behave differently under stressful conditions in humans as compared with mice, new research suggests. Because mice are a commonly used model for research in Parkinson’s disease, these “species-specific differences” could have important implications for how such research is done, according to a team of…

Many Who Start Antipsychotics Discontinue Treatment

More than a third of people with Parkinson’s disease who are prescribed antipsychotics stop treatment within six months of starting, a new database analysis suggests. The data also indicate that rates of treatment discontinuation are lower with Nuplazid (pimavanserin) than with other antipsychotics. The findings were published in …

MJFF Offering Online Guide for Patients Considering DBS

The Michael J. Fox Foundation (MJFF) has released a new guide that aims to help people with Parkinson’s disease and their loved ones make informed decisions about deep brain stimulation (DBS), a surgical treatment for the disorder’s motor symptoms. The 22-page guide, which is freely available online,…

Targeting Mitochondrial DNA May Be Therapeutic Strategy

In Parkinson’s disease, DNA that leaks out of mitochondria — small organelles that generate energy — leads to cell death and inflammation, according to a new study. The finding indicates that getting rid of this mitochondrial DNA could be a promising therapeutic strategy. The study, “Cytosolic dsDNA of…

FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch. In its response letter, the FDA said there was not enough evidence that the criteria evaluated…